A PYMNTS Company

Actavis Partly Settles Generic Intuniv Delay Case

By  |  August 20, 2020

Teva Pharmaceutical Industries unit Actavis has settled part of a sprawling antitrust lawsuit in Boston federal court claiming it conspired with Takeda Pharmaceuticals subsidiary Shire to delay generic versions of Shire’s ADHD drug Intuniv, reported Bloomberg Law. 

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The agreement, disclosed in a court filing Wednesday, August 19, resolves class action claims against Actavis by “direct purchasers” like wholesalers and major pharmacy chains that are challenging an earlier patent settlement between the two drugmakers.

    It doesn’t affect the claims against Shire or those brought by a separate proposed class of “indirect purchasers” like insurers.